ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,370Medicare Part D Prescriptions Filled, Including Refills

Rank: 73 out of 617

$684K Total Retail Price of All Prescriptions

Rank: 29 out of 617

361 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 361 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

18% of this provider’s 361 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

1% of this provider’s 9,336 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 519 451 1 2
OMEPRAZOLE 491 371 2 3
AMLODIPINE BESYLATE 445 370 3 6
METFORMIN HCL 342 265 4 9
ATORVASTATIN CALCIUM 315 273 5 14
RAMIPRIL 282 239 6 67
LOSARTAN POTASSIUM 278 257 7 22
HYDROCHLOROTHIAZIDE 277 262 8 13
METOPROLOL SUCCINATE 230 201 9 12
WARFARIN SODIUM 222 210 10 7
POTASSIUM CHLORIDE 208 159 11 10
CRESTOR 188 170 12 28
LEVOTHYROXINE SODIUM 187 142 13 1
BISOPROLOL FUMARATE 178 178 14 100
ENALAPRIL MALEATE 177 163 15 34
ZOLPIDEM TARTRATE 175 123 16 23
HYDROCODONE-ACETAMINOPHEN 174 124 S3 17 8
CITALOPRAM HBR 141 115 18 18
ISOSORBIDE MONONITRATE ER 129 128 19 52
PRAVASTATIN SODIUM 128 81 20 21
FUROSEMIDE 128 80 20 4
CHLORTHALIDONE 118 110 22 123
TAMSULOSIN HCL 115 106 23 26
TORSEMIDE 106 79 24 110
RANITIDINE HCL 106 75 24 40
METOPROLOL TARTRATE 103 85 26 11
LANTUS 91 58 27 39
PREDNISONE 88 87 28 31
CARVEDILOL 88 80 28 19
LISINOPRIL 88 84 28 5
ALLOPURINOL 88 80 28 27
SYNTHROID 86 72 32 59
GLIMEPIRIDE 84 69 33 33
CLONIDINE HCL 83 74 34 55
FLUTICASONE PROPIONATE 80 52 35 36
BENAZEPRIL HCL 79 55 36 44
SERTRALINE HCL 78 57 37 20
HUMALOG 78 71 37 152
WELCHOL 73 64 39 170
NOVOLOG 73 44 39 137
CLOPIDOGREL 72 61 41 53
AMLODIPINE BESYLATE-BENAZEPRIL 70 70 42 80
FENTANYL 68 67 S2 43 45
GABAPENTIN 66 46 44 16
SINGULAIR 59 44 45 106
PANTOPRAZOLE SODIUM 58 53 46 37
TRAZODONE HCL 55 47 47 51
ADVAIR DISKUS 54 50 48 38
LOSARTAN-HYDROCHLOROTHIAZIDE 54 52 48 46
ALENDRONATE SODIUM 54 42 48 25
TRICOR 52 35 51 83
TERAZOSIN HCL 50 50 52 96
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 17, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.